Gritstone Oncology Company

Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.
Technology: Biotechnology, Health Care, Therapeutics, Tumor-Specific Antigens
Industry: Clinical Development, Preclinical Development, Tumor-Specific Antigens
Headquarters: Emeryville, California, United States
Founded Date: 2015-08-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 16
Total Funding: 476000000
Estimated Revenue: $1M to $10M
Last Funding Date: 2022-07-22
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership